Delays in diagnosis and treatment of breast cancer: a multinational analysis

J Jassem, V Ozmen, F Bacanu… - … European journal of …, 2014 - academic.oup.com
Background: Reducing treatment delay improves outcomes in breast cancer. The aim of this
study was to determine factors influencing patient-and system-related delays in commencing …

[HTML][HTML] Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer …

J O'Shaughnessy, S Sousa, J Cruz, L Fallowfield… - European Journal of …, 2021 - Elsevier
Aim The aim of the study was to assess patient preference for the fixed-dose combination of
pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in patients with …

Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after …

PF Conte, A Schneeweiss, S Loibl, EP Mamounas… - Cancer, 2020 - Wiley Online Library
Background The phase 3 KATHERINE trial demonstrated significantly improved invasive
disease–free survival with adjuvant trastuzumab emtansine (T‐DM1) versus trastuzumab in …

[PDF][PDF] The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients

L Stamatovic, S Susnjar, D Gavrilovic, I Minic… - J BUON, 2018 - jbuon.com
Purpose: The objective of neoadjuvant chemotherapy (NACT) for locally advanced breast
cancer (LABC) is downstaging to achieve resectability. According to the protocol for the …

Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with …

A Schneeweiss, S Loibl, EP Mamounas, G Minckwitz… - 2019 - ascopubs.org
513 Background: The phase 3 KATHERINE (NCT01772472) study, met its primary endpoint
by demonstrating significantly improved invasive disease-free survival with adjuvant T-DM1 …

Efficacy and safety of oral NEPA (netupitant/palonosetron), the first fixed-combination antiemetic, in patients with gynecological cancers receiving platinum-based …

SM Bošnjak, L Stamatovic, ME Borroni… - International Journal of …, 2018 - ijgc.bmj.com
Objective Patients with gynecological cancers are at high risk for chemotherapy-induced
nausea and vomiting (CINV) after platinum-based chemotherapy (CT). NEPA (300-mg …

[PDF][PDF] Polymorphic expression of glutathione transferases A1, M1, P1 and T1 in epithelial ovarian cancer: a Serbian case-control study

I Pljesa, M Berisavac, T Simic, T Pekmezovic, V Coric… - j. BUON, 2017 - jbuon.com
Purpose: Since several studies have proposed that epithelial ovarian cancer should not be
considered as a single disease entity and that it results from an accumulation of genetic …

Novel BRCA1 splice-site mutation in ovarian cancer patients of Slavic origin

A Krivokuca, VS Dragos, L Stamatovic, A Blatnik… - Familial Cancer, 2018 - Springer
Mutations in breast cancer susceptibility gene 1 (BRCA1) lead to defects in a number of
cellular pathways including DNA damage repair and transcriptional regulation, resulting in …

Patient-related factors influencing time between first signs of breast cancer (BC) and appointment for medical visit (AMV): An international survey.

J Jassem, F Bacanu, J Eglitis, J Mardiak, T Pienkowski… - 2012 - ascopubs.org
9046 Background: Reducing diagnostic delays may improve treatment outcomes in BC. We
investigated in various countries patient-related factors influencing time to seeking medical …

Platinum–sensitive relapsed epithelial ovarian cancer: Not all the patients benefit from reinduction with carboplatin and paclitaxel

M Milovic-Kovacevic, L Stamatovic, I Popov… - Medical Science …, 2010 - medscimonit.com
Background: It is widely accepted that patients with ovarian cancer relapsing 6 to 12 months
after completion of a platinum-based regimen are considered to be partially platinum …